Dysregulation of dopamine metabolism in children with spinal muscular atrophy type 1
Abstract
Spinal muscular atrophy (SMA) is a severe neuromuscular disorder caused by reduced expression of the survival motor neuron (SMN) protein. In addition to affecting motor neuron survival, SMN deficiency impacts multisystem physiology and neurotransmission. Dopaminergic dysfunction has been reported in mouse models of SMA, leading to postural and locomotor impairments that improve following treatment with levodopa and benserazide, which increase central dopamine availability. However, whether altered dopamine metabolism contributes to clinical symptoms in SMA patients remains unclear. To investigate this issue, we conducted a real-world observational study involving paediatric patients with SMA type 1 (SMA1), SMA2, and SMA3, and healthy controls. We quantified the main dopamine-related catabolites—3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA)—in cerebrospinal fluid samples collected at baseline and after five intrathecal doses of Nusinersen, an SMN-enhancing therapy. No significant differences were observed in DOPAC and HVA levels across SMA types and controls or following treatment, and no association emerged with SMN2 copy number. In contrast, lower baseline DOPAC levels were detected in SMA1 patients requiring gastrostomy or tracheostomy, and were associated with reduced improvement following Nusinersen, as measured by changes in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders scores. Additional high-performance liquid chromatography analyses performed in an independent study cohort revealed significantly lower serum HVA levels in SMA1 patients compared to controls. In conclusion, our exploratory study suggests that altered dopaminergic metabolism is associated with greater disease severity and poorer motor outcomes following treatment, supporting an involvement of dopamine neurotransmission in clinical heterogeneity in SMA.
Related
- Management of Hip Instability in Spinal Muscular Atrophy in the Disease-Modifying Therapy Era: The “Late Autumn” or “Early Spring” of Neuro-Orthopedics?
- Computational identification and experimental validation of early glycinergic impairments in spinal muscular atrophy
- Prevalence of Hypovitaminosis D and Its Association with Motor Impairment in Spinal Muscular Atrophy
- CCN1-mediated stress signaling underlies intrinsic cardiomyocyte dysfunction in spinal muscular atrophy
- Beyond motor rescue: defining adequate SMN restoration in spinal muscular atrophy.
BibTeX
@article{nuzzo2026dysregulation,
title = {{Dysregulation of dopamine metabolism in children with spinal muscular atrophy type 1}},
author = {Tommaso Nuzzo and Barbara Risi and Valentina Bassareo and Adele D’Amico and Alberto Imarisio and Antonella Longo and Manolo Carta and Chiara Panicucci and Claudio Bruno and Enza Maria Valente and Massimiliano Filosto and Enrico Bertini and Francesco Errico and Alessandro Usiello},
journal = {Brain Communications},
year = {2026},
month = oct,
doi = {10.1093/braincomms/fcag402},
url = {https://doi.org/10.1093/braincomms/fcag402},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Dysregulation of dopamine metabolism in children with spinal muscular atrophy type 1
AU - Tommaso Nuzzo
AU - Barbara Risi
AU - Valentina Bassareo
AU - Adele D’Amico
AU - Alberto Imarisio
AU - Antonella Longo
AU - Manolo Carta
AU - Chiara Panicucci
AU - Claudio Bruno
AU - Enza Maria Valente
AU - Massimiliano Filosto
AU - Enrico Bertini
AU - Francesco Errico
AU - Alessandro Usiello
PY - 2026
DA - 2026/10/29
JO - Brain Communications
DO - 10.1093/braincomms/fcag402
UR - https://doi.org/10.1093/braincomms/fcag402
AB - Spinal muscular atrophy (SMA) is a severe neuromuscular disorder caused by reduced expression of the survival motor neuron (SMN) protein. In addition to affecting motor neuron survival, SMN deficiency impacts multisystem physiology and neurotransmission. Dopaminergic dysfunction has been reported in mouse models of SMA, leading to postural and locomotor impairments that improve following treatment with levodopa and benserazide, which increase central dopamine availability. However, whether altered dopamine metabolism contributes to clinical symptoms in SMA patients remains unclear. To investigate this issue, we conducted a real-world observational study involving paediatric patients with SMA type 1 (SMA1), SMA2, and SMA3, and healthy controls. We quantified the main dopamine-related catabolites—3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA)—in cerebrospinal fluid samples collected at baseline and after five intrathecal doses of Nusinersen, an SMN-enhancing therapy. No significant differences were observed in DOPAC and HVA levels across SMA types and controls or following treatment, and no association emerged with SMN2 copy number. In contrast, lower baseline DOPAC levels were detected in SMA1 patients requiring gastrostomy or tracheostomy, and were associated with reduced improvement following Nusinersen, as measured by changes in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders scores. Additional high-performance liquid chromatography analyses performed in an independent study cohort revealed significantly lower serum HVA levels in SMA1 patients compared to controls. In conclusion, our exploratory study suggests that altered dopaminergic metabolism is associated with greater disease severity and poorer motor outcomes following treatment, supporting an involvement of dopamine neurotransmission in clinical heterogeneity in SMA.
SN - 2632-1297
ER -